KDA
- Current
- Browse
- Collections
-
For contributors
- For Authors
- Instructions for authors
- Article processing charge
- e-submission
- For Reviewers
- Instructions for reviewers
- How to become a reviewer
- Best reviewers
- For Readers
- Readership
- Subscription
- Permission guidelines
- About
- Editorial policy
Search
- Page Path
- HOME > Search
Original Articles
- Others
- Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus
- Sejeong Park, So Young Park, Yu Jin Kim, Soo Min Hong, Suk Chon, Seungjoon Oh, Jeong-taek Woo, Sung-Woon Kim, Young Seol Kim, Sang Youl Rhee
- Diabetes Metab J. 2016;40(3):240-247. Published online April 5, 2016
- DOI: https://doi.org/10.4093/dmj.2016.40.3.240
- 6,079 View
- 67 Download
- 5 Web of Science
- 7 Crossref
-
Abstract
PDF
Supplementary Material
PubReader Background Gastrointestinal (GI) symptoms are common in patients with type 2 diabetes mellitus (T2DM). Rebamipide is an effective gastric cytoprotective agent, but there are few data on its usefulness in T2DM. The aim of this study is to evaluate the improvement of GI symptoms after rebamipide treatment in patients with T2DM.
Methods Patients with T2DM and atypical GI symptoms were enrolled. They took rebamipide (100 mg thrice daily) for 12 weeks and filled out the diabetes bowel symptom questionnaire (DBSQ) before and after rebamipide treatment. The DBSQ consisted of 10 questions assessing the severity of GI symptoms by a 1 to 6 scoring system. Changes in the DBSQ scores before and after rebamipide treatment were analyzed to evaluate any improvements of GI symptoms.
Results A total of 107 patients were enrolled, and 84 patients completed the study. The mean age was 65.0±7.8, 26 patients were male (24.8%), the mean duration of T2DM was 14.71±9.12 years, and the mean glycosylated hemoglobin level was 6.97%±0.82%. The total DBSQ score was reduced significantly from 24.9±8.0 to 20.4±7.3 before and after rebamipide treatment (
P <0.001). The DBSQ scores associated with reflux symptoms, indigestion, nausea or vomiting, abdominal bloating or distension, peptic ulcer, abdominal pain, and constipation were improved after rebamipide treatment (P <0.05). However, there were no significant changes in symptoms associated with irritable bowel syndrome, diarrhea, and anal incontinence. No severe adverse events were reported throughout the study.Conclusion Rebamipide treatment for 12 weeks improved atypical GI symptoms in patients with T2DM.
-
Citations
Citations to this article as recorded by
- INFLUENCE OF TYPE 2 DIABETES ON THE EFFICIENCY OF ENDOSCOPIC HEMOSTASIS FOR BLEEDING FROM PEPTIC GASTRODUODENAL ULCER
V. O. Shaprynskyi, M. V. Hmoshynskyi, V. R. Taheiev
Kharkiv Surgical School.2024; (2-3): 36. CrossRef - Effectiveness of Rebamipide as a part of the Helicobacter pylori eradication therapy in Russia: a meta-analysis of controlled trials
Dmitry N. Andreev, Igor V. Maev, Dmitry S. Bordin, Svetlana V. Lyamina, Diana T. Dicheva, Aleksei K. Fomenko, Armine S. Bagdasarian
Consilium Medicum.2022; 24(5): 333. CrossRef - Сompliance in patients with coronary heart disease and erosive-ulcerative gastroduodenopathy
A. R. Molchanova, A. I. Dolgushina, A. A. Seljanina
Experimental and Clinical Gastroenterology.2020; (6): 82. CrossRef - Rebamipide: evidence base for use in gastroenterology
D. N. Andreev, I. V. Maev
Terapevticheskii arkhiv.2020; 92(12): 97. CrossRef - Efficacy of Rebamipide in Organic and Functional Dyspepsia: A Systematic Review and Meta-Analysis
Mohamed Hasif Jaafar, Sher Zaman Safi, Maw-Pin Tan, Sanjay Rampal, Sanjiv Mahadeva
Digestive Diseases and Sciences.2018; 63(5): 1250. CrossRef - Letter: Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J2016;40:240-7)
Jin Hwa Kim
Diabetes & Metabolism Journal.2016; 40(4): 334. CrossRef - Response: Effects of Rebamipide on Gastrointestinal Symptoms in Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2016;40:240-7)
Sejeong Park, So Young Park, Sang Youl Rhee
Diabetes & Metabolism Journal.2016; 40(4): 336. CrossRef
- INFLUENCE OF TYPE 2 DIABETES ON THE EFFICIENCY OF ENDOSCOPIC HEMOSTASIS FOR BLEEDING FROM PEPTIC GASTRODUODENAL ULCER
- Risk Factors for the Progression of Intima-Media Thickness of Carotid Arteries: A 2-Year Follow-Up Study in Patients with Newly Diagnosed Type 2 Diabetes
- Sang Ouk Chin, Jin Kyung Hwang, Sang Youl Rhee, Suk Chon, You-Cheol Hwang, Seungjoon Oh, Kyu Jeung Ahn, Ho Yeon Chung, Jeong-taek Woo, Sung-Woon Kim, Young Seol Kim, Ja-Heon Kang, In-Kyung Jeong
- Diabetes Metab J. 2013;37(5):365-374. Published online October 17, 2013
- DOI: https://doi.org/10.4093/dmj.2013.37.5.365
- 5,400 View
- 40 Download
- 6 Crossref
-
Abstract
PDFSupplementary MaterialPubReader
Background Intima-media thickness (IMT) of the carotid arteries is known to have a positive correlation with the risk of cardiovascular disease. This study was designed to identify risk factors affecting the progression of carotid IMT in patients with type 2 diabetes mellitus (T2DM).
Methods Patients with newly diagnosed T2DM with carotid IMT measurements were enrolled, and their clinical data and carotid IMT results at baseline and 2 years later were compared.
Results Of the 171 patients, 67.2% of males and 50.8% of females had abnormal baseline IMT of the left common carotid artery. At baseline, systolic blood pressure, body mass index and smoking in male participants, and fasting plasma glucose and glycated hemoglobin levels in females were significantly higher in patients with abnormal IMT than in those with normal IMT. Low density lipoprotein cholesterol (LDL-C) levels in males and high density lipoprotein cholesterol (HDL-C) levels in females at the 2-year follow-up were significantly different between the nonprogression and the progression groups. Reduction of the United Kingdom Prospective Diabetes Study (UKPDS) 10-year coronary heart disease (CHD) risk score after 2 years was generally higher in the nonprogression group than the progression group.
Conclusion LDL-C levels in males and HDL-C levels in females at the 2-year follow-up were significantly different between participants with and without progression of carotid IMT. Furthermore, a reduction in the UKPDS 10-year CHD risk score appeared to delay the advancement of atherosclerosis. Therefore, the importance of establishing the therapeutic goal of lipid profiles should be emphasized to prevent the progression of carotid IMT in newly diagnosed T2DM patients.
-
Citations
Citations to this article as recorded by- Comparison of the Effectiveness of Low Carbohydrate Versus Low Fat Diets, in Type 2 Diabetes: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Tanefa A. Apekey, Maria J. Maynard, Monia Kittana, Setor K. Kunutsor
Nutrients.2022; 14(20): 4391. CrossRef Nomogram Based on Risk Factors for Type 2 Diabetes Mellitus Patients with Coronary Heart Disease
Rong Shi, Birong Wu, Zheyun Niu, Hui Sun, Fan Hu
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2020; Volume 13: 5025. CrossRef- HMGA1 Mediated High-Glucose-Induced Vascular Smooth Muscle Cell Proliferation in Diabetes Mellitus: Association Between PI3K/Akt Signaling and HMGA1 Expression
Qinghai Zhang, Ling Chen, Zhibo Zhao, Ying Wu, Jing Zhong, Gebo Wen, Renxian Cao, Xuyu Zu, Jianghua Liu
DNA and Cell Biology.2018; 37(4): 389. CrossRef - Relationship between frequency of hypoglycemic episodes and changes in carotid atherosclerosis in insulin-treated patients with type 2 diabetes mellitus
Tomoya Mita, Naoto Katakami, Toshihiko Shiraiwa, Hidenori Yoshii, Nobuichi Kuribayashi, Takeshi Osonoi, Hideaki Kaneto, Keisuke Kosugi, Yutaka Umayahara, Masahiko Gosho, Iichiro Shimomura, Hirotaka Watada
Scientific Reports.2017;[Epub] CrossRef - Impact of carotid atherosclerosis detection on physician and patient behavior in the management of type 2 diabetes mellitus: a prospective, observational, multicenter study
In-Kyung Jeong, Sin-Gon Kim, Dong Hyeok Cho, Chong Hwa Kim, Chul Sik Kim, Won-Young Lee, Kyu-Chang Won, Doo-Man Kim
BMC Cardiovascular Disorders.2016;[Epub] CrossRef - The effect of fibroblast growth factors and advanced glycation end-products on the intima-media complex thickness in patients with coronary heart disease and type 2 diabetes
Ekaterina Vladimirovna Ivannikova, Victor Yurievich Kalashnikov, Olga Mikhailovna Smirnova, Alexander Borisovich Kuznetsov, Сергей Anatolievich Terekhin, Alexander Viktorovich Il'in
Diabetes mellitus.2014; 17(2): 47. CrossRef
- Comparison of the Effectiveness of Low Carbohydrate Versus Low Fat Diets, in Type 2 Diabetes: Systematic Review and Meta-Analysis of Randomized Controlled Trials
- Autoimmune Hypoglycemia in a Patient with Characterization of Insulin Receptor Autoantibodies
- Suk Chon, Moon Chan Choi, Yun Jung Lee, You Cheol Hwang, In-Kyung Jeong, Seungjoon Oh, Kyu Jeung Ahn, Ho Yeon Chung, Jeong-Taek Woo, Sung-Woon Kim, Jin-Woo Kim, Young Seol Kim
- Diabetes Metab J. 2011;35(1):80-85. Published online February 28, 2011
- DOI: https://doi.org/10.4093/dmj.2011.35.1.80
- 5,969 View
- 51 Download
- 19 Crossref
-
Abstract
PDFPubReader
Background Type B insulin resistance syndrome is a manifestation of autoantibodies to the insulin receptor that results in severe hyperglycemia and acanthosis nigricans. However, the mechanisms by which these autoantibodies induce hypoglycemia are largely unknown. In this paper, we report the case of patient with type B insulin resistance syndrome who presented with frequent severe fasting hypoglycemia and acanthosis nigricans.
Methods To evaluate the mechanism of hypoglycemia, we measured the inhibition of insulin binding to erythrocytes and IM9 lymphocytes in a sample of the patient's dialyzed serum before and after immunosuppressive therapy.
Results In the patient's pre-treatment serum IgG, the binding of 125I-insulin to erythrocytes was markedly inhibited in a dose-dependent manner until the cold insulin level reached 10-9 mol/L. We also observed dose-dependent inhibition of insulin binding to IM9 lymphocytes, which reached approximately 82% inhibition and persisted even when diluted 1:20. After treatment with glucocorticoids, insulin-erythrocyte binding activity returned to between 70% and 80% of normal, while the inhibition of insulin-lymphocyte binding was reduced by 17%.
Conclusion We treated a patient with type B insulin resistance syndrome showing recurrent fasting hypoglycemia with steroids and azathioprine. We characterized the patient's insulin receptor antibodies by measuring the inhibition of insulin binding.
-
Citations
Citations to this article as recorded by- Systematic Review—Type B Insulin Resistance With Isolated Hypoglycemia and Suppressed Insulin
Natasha Brown, Marianne S Elston
The Journal of Clinical Endocrinology & Metabolism.2024; 109(4): 936. CrossRef - Type B insulin resistance syndrome: a systematic review
Luizianne Mariano Martins, Virgínia Oliveira Fernandes, Manuela Montenegro Dias de Carvalho, Daniel Duarte Gadelha, Paulo Cruz de Queiroz, Renan Magalhães Montenegro
Archives of Endocrinology and Metabolism.2020;[Epub] CrossRef - Autoimmune hypoglycemia
Marina Y. Yukina, Diana A. Davtyan, Ekaterina A. Troshina, Nurana F. Nuralieva
Obesity and metabolism.2018; 15(3): 9. CrossRef - Unique pharmacology of a novel allosteric agonist/sensitizer insulin receptor monoclonal antibody
Simon A. Hinke, Anne M. Cieniewicz, Thomas Kirchner, Katharine D'Aquino, Rupesh Nanjunda, Jason Aligo, Robert Perkinson, Philip Cooper, Ken Boayke, Mark L. Chiu, Steve Jarantow, Eilyn R. Lacy, Yin Liang, Dana L. Johnson, Jean M. Whaley, Russell B. Lingham
Molecular Metabolism.2018; 10: 87. CrossRef - Combined Immunosuppressive Therapy Induces Remission in Patients With Severe Type B Insulin Resistance: A Prospective Cohort Study
Joanna Klubo-Gwiezdzinska, Maria Lange, Elaine Cochran, Robert K. Semple, Cornelia Gewert, Rebecca J. Brown, Phillip Gorden
Diabetes Care.2018; 41(11): 2353. CrossRef - Hypoinsulinemic Hypoglycemia Followed By The Onset Of Severe Insulin Resistance With Hyperglycemia And Circulating Anti-Insulin Receptor Antibodies In A Patient Suffering Systemic Lupus Erythematosus: A Case Report And Literature Review
Guillermo Martínez de Pinillos, Mariana Tomé, María M. Viloria, Joaquín Bobillo, María V. Cózar
AACE Clinical Case Reports.2017; 3(3): e284. CrossRef - The treatment of hyperinsulinemic hypoglycaemia in adults: an update
M. V. Davi′, A. Pia, V. Guarnotta, G. Pizza, A. Colao, A. Faggiano
Journal of Endocrinological Investigation.2017; 40(1): 9. CrossRef - Immunosuppressive Therapy in Treatment of Refractory Hypoglycemia in Type B Insulin Resistance: A Case Report
Lavanya Viswanathan, Imali Sirisena
Journal of the Endocrine Society.2017; 1(12): 1435. CrossRef - 反復する低血糖発作を契機に発見されたインスリン受容体異常症B型の1例(A case of type B insulin resistance presenting as recurrent hypoglycemia)
杉本 龍 (Ryu Sugimoto), 髙木 誠 (Makoto Takaki), 前原 潤一 (Junichi Maehara), 具嶋 泰弘 (Yasuhiro Gushima)
Nihon Kyukyu Igakukai Zasshi: Journal of Japanese Association for Acute Medicine.2017; 28(3): 100. CrossRef - Type B insulin resistance syndrome
Devina L. Willard, Mary Stevenson, Devin Steenkamp
Current Opinion in Endocrinology, Diabetes & Obesity.2016; 23(4): 318. CrossRef - Antibody-Mediated Insulin Resistance: When Insulin and Insulin Receptor Act as Autoantigens in Humans
Christelle Liminet, Julien Vouillarmet, Karim Chikh, Emmanuel Disse
Canadian Journal of Diabetes.2016; 40(5): 462. CrossRef - The insulin autoimmune syndrome (IAS) as a cause of hypoglycaemia: an update on the pathophysiology, biochemical investigations and diagnosis
Adel A.A. Ismail
Clinical Chemistry and Laboratory Medicine (CCLM).2016; 54(11): 1715. CrossRef - Type B insulin-resistance syndrome presenting as autoimmune hypoglycemia, associated with systemic lupus erythematosus and interstitial lung disease
Seon Mee Kang, Heung Yong Jin, Kyung Ae Lee, Ji Hyun Park, Hong Sun Baek, Tae Sun Park
The Korean Journal of Internal Medicine.2013; 28(1): 98. CrossRef - Treatment of recurrent hypoglycemia with plasmapheresis and steroid in nondiabetic patient
Mustafa Kulaksızoglu, Mustafa Sait Gonen, Levent Kebapcilar, Fatih Sahin, Fatih Demirci, Ali Topcu
Transfusion and Apheresis Science.2013; 48(1): 11. CrossRef - A Case of Persistent Hypoglycemia: When to Think Outside the Box
Yogeswari Venugopal, Shireene Vethakkan, Sargunan Sockalingam, Raja Jasmin, Karen Choong
Clinical Diabetes.2013; 31(3): 130. CrossRef - The effect of hyperglycemia and hypoglycemia on glucose transport and expression of glucose transporters in human lymphocytes B and T: An in vitro study
Bożenna Oleszczak, Leszek Szablewski, Monika Pliszka
Diabetes Research and Clinical Practice.2012; 96(2): 170. CrossRef - The effect of glucose concentrations in the medium on expression of insulin receptors in human lymphocytes B and T: anin vitrostudy
Bożenna Oleszczak, Leszek Szablewski, Monika Pliszka
Journal of Receptors and Signal Transduction.2012; 32(5): 263. CrossRef - Fulminant Type 1 diabetes in a pregnant woman as an initial manifestation of the insulin autoimmune syndrome
H. S. Kim, T.‐Y. Lee, E. Y. Kim, J. H. Choi, S. Y. Kim, Y.‐C. Hwang, J.‐H. Kang, K. J. Ahn, H. Y. Chung, I.‐K. Jeong
Diabetic Medicine.2012; 29(10): 1335. CrossRef - A Case of the Type B Insulin Resistance Syndrome with Chronic Hepatitis B
Hyun Seok Choi, Byoung Ho Choi, Seok Hoo Jeong, Shung Han Choi, Dong Su Shin, Sei hyun Kim, Young Sil Eom, Sihoon Lee, Yeun Sun Kim, Ie Byung Park, Ki Young Lee
Endocrinology and Metabolism.2011; 26(4): 360. CrossRef
- Systematic Review—Type B Insulin Resistance With Isolated Hypoglycemia and Suppressed Insulin
First
Prev
